Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2024 Jun 17;24(1):283.
doi: 10.1186/s12890-024-03083-w.

A comparative analysis of sivelestat sodium hydrate and ulinastatin combination therapy in the treatment of sepsis with acute respiratory distress syndrome

Jian Xu #  1   2 , Chenfei Zhang #  3 , Keren Wu #  4 , Yanhua Qian  5   6 , Wei Hu  7
Affiliations
Comparative Study

A comparative analysis of sivelestat sodium hydrate and ulinastatin combination therapy in the treatment of sepsis with acute respiratory distress syndrome

Jian Xu et al. BMC Pulm Med. .

Abstract

Objective: This comparative analysis aimed to investigate the efficacy of Sivelestat Sodium Hydrate (SSH) combined with Ulinastatin (UTI) in the treatment of sepsis with acute respiratory distress syndrome (ARDS).

Methods: A control group and an observation group were formed with eighty-four cases of patients with sepsis with ARDS, with 42 cases in each group. The control group was intravenously injected with UTI based on conventional treatment, and the observation group was injected with SSH based on the control group. Both groups were treated continuously for 7 days, and the treatment outcomes and efficacy of both groups were observed. The Murray Lung Injury Score (MLIS), Sequential Organ Failure Assessment (SOFA), and Acute Physiology and Chronic Health Evaluation II (APACHE II) were compared. Changes in respiratory function, inflammatory factors, and oxidative stress indicators were assessed. The occurrence of adverse drug reactions was recorded.

Results: The total effective rate in the observation group (95.24%) was higher than that in the control group (80.95%) (P < 0.05). The mechanical ventilation time, intensive care unit (ICU) hospitalization time, and duration of antimicrobial medication in the observation group were shorter and multiple organ dysfunction syndrome incidence was lower than those in the control group (P < 0.05). The mortality rate of patients in the observation group (35.71%) was lower than that in the control group (52.38%), but there was no statistically significant difference between the two groups (P > 0.05). MLIS, SOFA, and APACHE II scores in the observation group were lower than the control group (P < 0.05). After treatment, respiratory function, inflammation, and oxidative stress were improved in the observation group (P < 0.05). Adverse reactions were not significantly different between the two groups (P > 0.05).

Conclusion: The combination of SSH plus UTI improves lung injury and pulmonary ventilation function, and reduces inflammation and oxidative stress in patients with sepsis and ARDS.

Keywords: Adverse reactions; Inflammation; Oxidative stress; Respiratory function; Sepsis with acute respiratory distress syndrome; Sivelestat sodium hydrate; Therapeutic efficacy; Ulinastatin.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Flowchart for case enrollment
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Mirijello A, Tosoni A. and G. On behalf of the internal medicine sepsis study, New strategies for treatment of sepsis. Med (Kaunas). 2020;56(10). - PMC - PubMed
    1. Rello J, et al. Sepsis: a review of advances in management. Adv Ther. 2017;34(11):2393–411. doi: 10.1007/s12325-017-0622-8. - DOI - PMC - PubMed
    1. Caraballo C, Jaimes F. Organ dysfunction in Sepsis: an ominous trajectory from infection to death. Yale J Biol Med. 2019;92(4):629–40. - PMC - PubMed
    1. Xu H, et al. Acute respiratory distress syndrome heterogeneity and the septic ARDS subgroup. Front Immunol. 2023;14:1277161. doi: 10.3389/fimmu.2023.1277161. - DOI - PMC - PubMed
    1. Hu Q, Hao C, Tang S. From sepsis to acute respiratory distress syndrome (ARDS): emerging preventive strategies based on molecular and genetic researches. Biosci Rep. 2020;40(5). - PMC - PubMed

Publication types

MeSH terms

-